AI Verdict
HRMY has stronger fundamentals based on our AI analysis.
HRMY vs HRGN Fundamental Comparison
| Metric | HRMY | HRGN |
|---|---|---|
| Revenue | $868.5M | $704,000.0 |
| Net Income | $158.7M | $-6.9M |
| Net Margin | 18.3% | -975.7% |
| ROE | 18.2% | -649.9% |
| ROA | 12.5% | -256.6% |
| Current Ratio | 3.60x | 1.19x |
| Debt/Equity | 0.19x | 0.00x |
| EPS | $2.71 | $-0.44 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
HRMY vs HRGN: Frequently Asked Questions
Is HRMY or HRGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), HRMY has stronger fundamentals. HRMY is rated BUY (78% confidence) while HRGN is rated STRONG SELL (85% confidence). This is not investment advice.
How does HRMY compare to HRGN fundamentally?
Harmony Biosciences Holdings, Inc. has ROE of 18.2% vs Harvard Apparatus Regenerative Technology, Inc.'s -649.9%. Net margins are 18.3% vs -975.7% respectively.
Which stock pays higher dividends, HRMY or HRGN?
HRMY has a dividend yield of N/A or no dividend while HRGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in HRMY or HRGN for long term?
For long-term investing, consider that HRMY has BUY rating with 78% confidence, while HRGN has STRONG SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about HRMY vs HRGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For HRMY vs HRGN, the AI consensus favors HRMY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.